These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
413 related articles for article (PubMed ID: 12746841)
1. Anti-proliferative and apoptotic effects of anandamide in human prostatic cancer cell lines: implication of epidermal growth factor receptor down-regulation and ceramide production. Mimeault M; Pommery N; Wattez N; Bailly C; Hénichart JP Prostate; 2003 Jun; 56(1):1-12. PubMed ID: 12746841 [TBL] [Abstract][Full Text] [Related]
2. Synergistic antiproliferative and apoptotic effects induced by mixed epidermal growth factor receptor inhibitor ZD1839 and nitric oxide donor in human prostatic cancer cell lines. Mimeault M; Jouy N; Depreux P; Hénichart JP Prostate; 2005 Feb; 62(2):187-99. PubMed ID: 15389789 [TBL] [Abstract][Full Text] [Related]
3. Synergistic antiproliferative and apoptotic effects induced by epidermal growth factor receptor and protein kinase a inhibitors in human prostatic cancer cell lines. Mimeault M; Pommery N; Hénichart JP Int J Cancer; 2003 Aug; 106(1):116-24. PubMed ID: 12794766 [TBL] [Abstract][Full Text] [Related]
4. Novel combination therapy against metastatic and androgen-independent prostate cancer by using gefitinib, tamoxifen and etoposide. Mimeault M; Venkatraman G; Johansson SL; Moore E; Henichart JP; Depreux P; Lin MF; Batra SK Int J Cancer; 2007 Jan; 120(1):160-9. PubMed ID: 17013895 [TBL] [Abstract][Full Text] [Related]
5. Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation. Melck D; De Petrocellis L; Orlando P; Bisogno T; Laezza C; Bifulco M; Di Marzo V Endocrinology; 2000 Jan; 141(1):118-26. PubMed ID: 10614630 [TBL] [Abstract][Full Text] [Related]
6. Complex post-transcriptional regulation of EGF-receptor expression by EGF and TGF-alpha in human prostate cancer cells. Seth D; Shaw K; Jazayeri J; Leedman PJ Br J Cancer; 1999 May; 80(5-6):657-69. PubMed ID: 10360641 [TBL] [Abstract][Full Text] [Related]
7. Cytotoxic effects induced by a combination of cyclopamine and gefitinib, the selective hedgehog and epidermal growth factor receptor signaling inhibitors, in prostate cancer cells. Mimeault M; Moore E; Moniaux N; Hénichart JP; Depreux P; Lin MF; Batra SK Int J Cancer; 2006 Feb; 118(4):1022-31. PubMed ID: 16108016 [TBL] [Abstract][Full Text] [Related]
8. Involvement of the cAMP/protein kinase A pathway and of mitogen-activated protein kinase in the anti-proliferative effects of anandamide in human breast cancer cells. Melck D; Rueda D; Galve-Roperh I; De Petrocellis L; Guzmán M; Di Marzo V FEBS Lett; 1999 Dec; 463(3):235-40. PubMed ID: 10606728 [TBL] [Abstract][Full Text] [Related]
9. The cannabinoid R+ methanandamide induces IL-6 secretion by prostate cancer PC3 cells. Olea-Herrero N; Vara D; Malagarie-Cazenave S; Díaz-Laviada I J Immunotoxicol; 2009 Dec; 6(4):249-56. PubMed ID: 19908944 [TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor receptor monoclonal antibody inhibits constitutive receptor phosphorylation, reduces autonomous growth, and sensitizes androgen-independent prostatic carcinoma cells to tumor necrosis factor alpha. Fong CJ; Sherwood ER; Mendelsohn J; Lee C; Kozlowski JM Cancer Res; 1992 Nov; 52(21):5887-92. PubMed ID: 1394216 [TBL] [Abstract][Full Text] [Related]
11. Anti-proliferative effects of evodiamine on human prostate cancer cell lines DU145 and PC3. Kan SF; Yu CH; Pu HF; Hsu JM; Chen MJ; Wang PS J Cell Biochem; 2007 May; 101(1):44-56. PubMed ID: 17340628 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of human tumour prostate PC-3 cell growth by cannabinoids R(+)-Methanandamide and JWH-015: involvement of CB2. Olea-Herrero N; Vara D; Malagarie-Cazenave S; Díaz-Laviada I Br J Cancer; 2009 Sep; 101(6):940-50. PubMed ID: 19690545 [TBL] [Abstract][Full Text] [Related]
13. Androgen up-regulates epidermal growth factor receptor expression and binding affinity in PC3 cell lines expressing the human androgen receptor. Brass AL; Barnard J; Patai BL; Salvi D; Rukstalis DB Cancer Res; 1995 Jul; 55(14):3197-203. PubMed ID: 7606741 [TBL] [Abstract][Full Text] [Related]
14. Improvement of cytotoxic effects induced by mitoxantrone on hormone-refractory metastatic prostate cancer cells by co-targeting epidermal growth factor receptor and hedgehog signaling cascades. Mimeault M; Mehta PP; Hauke R; Henichart JP; Depreux P; Lin MF; Batra SK Growth Factors; 2007 Dec; 25(6):400-16. PubMed ID: 18365871 [TBL] [Abstract][Full Text] [Related]
15. Targeted inhibition of the epidermal growth factor receptor-tyrosine kinase by ZD1839 ('Iressa') induces cell-cycle arrest and inhibits proliferation in prostate cancer cells. Sgambato A; Camerini A; Faraglia B; Ardito R; Bianchino G; Spada D; Boninsegna A; Valentini V; Cittadini A J Cell Physiol; 2004 Oct; 201(1):97-105. PubMed ID: 15281092 [TBL] [Abstract][Full Text] [Related]
16. Lycopene differentially induces quiescence and apoptosis in androgen-responsive and -independent prostate cancer cell lines. Ivanov NI; Cowell SP; Brown P; Rennie PS; Guns ES; Cox ME Clin Nutr; 2007 Apr; 26(2):252-63. PubMed ID: 17337101 [TBL] [Abstract][Full Text] [Related]
17. Distinct effects of ceramide-generating pathways in prostate adenocarcinoma cells. Condorelli F; Canonico PL; Sortino MA Br J Pharmacol; 1999 May; 127(1):75-84. PubMed ID: 10369458 [TBL] [Abstract][Full Text] [Related]
18. The endogenous cannabinoid, anandamide, induces cell death in colorectal carcinoma cells: a possible role for cyclooxygenase 2. Patsos HA; Hicks DJ; Dobson RR; Greenhough A; Woodman N; Lane JD; Williams AC; Paraskeva C Gut; 2005 Dec; 54(12):1741-50. PubMed ID: 16099783 [TBL] [Abstract][Full Text] [Related]
19. A comparison of EDHF-mediated and anandamide-induced relaxations in the rat isolated mesenteric artery. White R; Hiley CR Br J Pharmacol; 1997 Dec; 122(8):1573-84. PubMed ID: 9422801 [TBL] [Abstract][Full Text] [Related]
20. Developmental aspects of anandamide: ontogeny of response and prenatal exposure. Fride E; Mechoulam R Psychoneuroendocrinology; 1996 Feb; 21(2):157-72. PubMed ID: 8774060 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]